These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20495538)

  • 21. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
    Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
    Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Halfdanarson TR; Muders MH; Ames MM
    Pancreas; 2013 Apr; 42(3):411-21. PubMed ID: 23211371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
    APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.
    Nikiforova MN; Khalid A; Fasanella KE; McGrath KM; Brand RE; Chennat JS; Slivka A; Zeh HJ; Zureikat AH; Krasinskas AM; Ohori NP; Schoedel KE; Navina S; Mantha GS; Pai RK; Singhi AD
    Mod Pathol; 2013 Nov; 26(11):1478-87. PubMed ID: 23743931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation of epidermal growth factor receptor and estrogen receptor-independent pS2 protein to the malignant transformation of mucinous cystic neoplasms of the pancreas.
    Kirby RE; Lewandrowski KB; Southern JF; Compton CC; Warshaw AL
    Arch Surg; 1995 Jan; 130(1):69-72. PubMed ID: 7802579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: a morphologic and molecular correlation study.
    Xiong J; He M; Jackson C; Ou JJ; Sung CJ; Breese V; Steinhoff MM; Quddus MR; Tejada-Berges T; Lawrence WD
    Int J Gynecol Cancer; 2013 Sep; 23(7):1231-6. PubMed ID: 23851676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Will molecular diagnostics become established in pancreatic pathology?].
    Sipos B; Sperveslage J
    Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
    Mikhitarian K; Pollen M; Zhao Z; Shyr Y; Merchant NB; Parikh A; Revetta F; Washington MK; Vnencak-Jones C; Shi C
    Mod Pathol; 2014 May; 27(5):665-74. PubMed ID: 24186143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
    Anglesio MS; Arnold JM; George J; Tinker AV; Tothill R; Waddell N; Simms L; Locandro B; Fereday S; Traficante N; Russell P; Sharma R; Birrer MJ; ; deFazio A; Chenevix-Trench G; Bowtell DD
    Mol Cancer Res; 2008 Nov; 6(11):1678-90. PubMed ID: 19010816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.
    Bongers G; Muniz LR; Pacer ME; Iuga AC; Thirunarayanan N; Slinger E; Smit MJ; Reddy EP; Mayer L; Furtado GC; Harpaz N; Lira SA
    Gastroenterology; 2012 Sep; 143(3):730-740. PubMed ID: 22643351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.
    de Vries M; Bruijn IB; Cleton-Jansen AM; Malessy MJ; van der Mey AG; Hogendoorn PC
    Virchows Arch; 2013 Feb; 462(2):211-7. PubMed ID: 23224067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases.
    Thompson LD; Becker RC; Przygodzki RM; Adair CF; Heffess CS
    Am J Surg Pathol; 1999 Jan; 23(1):1-16. PubMed ID: 9888699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions.
    Panarelli NC; Sela R; Schreiner AM; Crapanzano JP; Klimstra DS; Schnoll-Sussman F; Pochapin MB; Yantiss RK
    Am J Surg Pathol; 2012 Oct; 36(10):1434-43. PubMed ID: 22982886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.
    Zimmer S; Kahl P; Buhl TM; Steiner S; Wardelmann E; Merkelbach-Bruse S; Buettner R; Heukamp LC
    J Cancer Res Clin Oncol; 2009 May; 135(5):723-30. PubMed ID: 19002495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.